Rigel Pharmaceuticals Inc expected to post earnings of 47 cents a share - Earnings Preview

Rigel Pharmaceuticals

28/02/2025 21:04

Rigel Pharmaceuticals Inc RIGL.OQ RIGL.O is expected to show a rise in quarterly revenue when it reports  results on March 4 for the period ending December 31 2024

The South San Francisco California-based  company is expected to report a 44.5% increase in revenue to $51.732 million from $35.79 million a year ago, according to the mean estimate from 6 analysts, based on LSEG data.

​LSEG's mean analyst estimate for Rigel Pharmaceuticals Inc is for earnings of 47 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," 4 "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Rigel Pharmaceuticals Inc is $23.00​, above​ its last closing price of $21.78. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Sep. 30 2024
0.08
0.06
0.70
Beat
1,100.1
Jun. 30 2024
-0.28
-0.29
-0.06
Beat
79.5
Mar. 31 2024
-0.27
-0.29
-0.50
Missed
-73.4​
Dec. 31 2023
-0.27
-0.30
0.00
Beat
100
​​Sep. 30 2023
-0.72
-0.71
-0.30
Beat
57.7
Jun. 30 2023
-0.78
-0.78
-0.40
Beat
48.7​
Mar. 31 2023
-0.95
-0.97
-0.80
Beat
17.9
Dec. 31 2022
-1.09
-1.12
0.10
Beat
108.9

This summary was machine generated February 28 at 21:04 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)